Retigabine, a K V7 (KCNQ) potassium channel opener, attenuates l-DOPA-induced dyskinesias in 6-OHDA-lesioned rats

Neuropharmacology

Volumn 62, Issue 2, 2012, Pages 1052-1061

  Sander, S E ^a   Lemm, C ^a   Lange, N ^a   Hamann, M ^a   Richter, A ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Amantadine; Dyskinesia; Flupirtine; M currents; Movement disorders; Parkinson's disease; Potassium; Retigabine; XE 991

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; AMANTADINE; FLUPIRTINE; LEVODOPA; OXIDOPAMINE; POTASSIUM CHANNEL KCNQ; POTASSIUM CHANNEL STIMULATING AGENT; RETIGABINE;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDYSKINETIC EFFECT; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BEHAVIOR CHANGE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DYSKINESIA; FEMALE; LOCOMOTION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SEDATION;

AMANTADINE; AMINOPYRIDINES; ANIMALS; ANTICONVULSANTS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; CARBAMATES; DYSKINESIA, DRUG-INDUCED; FEMALE; MOTOR ACTIVITY; OXIDOPAMINE; PHENYLENEDIAMINES; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPED BEHAVIOR;

EID: 84855918096     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.10.016     Document Type: Article

References (53)

1. G. Blackburn-Munro, W. Dalby-Brown, N.R. Mirza, J.D. Mikkelsen, and R.E. Blackburn-Munro Retigabine: chemical synthesis to clinical application CNS Drug Rev. 11 2005 1 20
2. D.A. Brown, and G.M. Passmore Neural KCNQ (Kv7) channels Br. J. Pharmacol. 156 2009 1185 1195
3. K. Buck, and B. Ferger L-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective Drug Discov. Today 15 2010 867 875
4. P. Calabresi, B. Picconi, L. Parnetti, and M. Di Filippo A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance Lancet Neurol. 5 2006 974 983
5. M.A. Cenci Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia Trends Neurosci. 30 2007 236 243
6. M.A. Cenci, and M. Lundblad Utility of 6-hydroxydopamine lesioned rats in the preclinical screening of novel treatments of Parkinson disease M. LeDoux, Animal Models of Movement Disorders 2005 Elsevier Academic Press San Diego 193 208
7. A. Dekundy, M. Lundblad, W. Danysz, and M.A. Cenci Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model Behav. Brain Res. 179 2007 76 89
8. F. Del Sorbo, and A. Albanese Levodopa-induced dyskinesias and their management J. Neurol. 255 Suppl. 4 2008 32 41
9. M. Deogaonkar, and T. Subramanian Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease Brain Res. Rev. 50 2005 156 168
10. J.J. Devaux, K.A. Kleopa, E.C. Cooper, and S.S. Scherer KCNQ2 is a nodal K+ channel J. Neurosci. 24 2004 1236 1244
11. R. Dost, A. Rostock, and C. Rundfeldt The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation Naunyn- Schmiedeberg's Arch. Pharmacol. 369 2004 382 390
12. G. Fabbrini, J.M. Brotchie, F. Grandas, M. Nomoto, and C.G. Goetz L-DOPA-induced dyskinesias Mov. Disord. 22 2007 1379 1389
13. S. Fahn The spectrum of L-DOPA-induced dyskinesias Ann. Neurol. 47 4 Suppl. 1 2000 2 11
14. H.-H. Frey Tolerance and dependence H.-H. Frey, D. Janz, Handbook of Experimental Pharmacology: Antiepileptic Drugs vol. 74 1985 Springer-Verlag Berlin 265 282
15. A.A. Grace Physiology of the normal and dopamine-depleted basal ganglia: insights into L-DOPA pharmacotherapy Mov. Disord. 23 Suppl. 3 2008 S560 S569
16. H.H. Hansen, O. Waroux, V. Seutin, T.J. Jentsch, S. Aznar, and J.D. Mikkelsen Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS J. Physiol. 586 2008 1823 1832
17. W.M. Herrmann, R. Hiersemenzel, M. Aigner, M. Lobisch, H. Riethmuller-Winzen, and I. Michel Long-term tolerance of flupirtine. Open multicenter study over one year Fortschr. Med. 111 1993 266 270
18. V.I. Ilyen, K.P. Carlin, D.D. Hodges, S. Robledo, and R.M. Woodward Flupirtine - a positive modulator of heteromeric KCNQ2/3 channels Neuroscience 2002 Orlando, Florida
19. J. Jankovic Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations Mov. Disord. 20 Suppl. 11 2005 S11 S16
20. T. Kharkovets, J.P. Hardelin, S. Safieddine, M. Schweizer, A. El-Amraoui, and C. Petit KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway Proc. Natl. Acad. Sci. USA 97 2000 4333 4338
21. M.P. Korsgaard, B.P. Hartz, W.D. Brown, P.K. Ahring, D. Strobaek, and N.R. Mirza Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels J. Pharmacol. Exp. Ther. 314 2005 282 292
22. P.M. Lang, J. Fleckenstein, G.M. Passmore, D.A. Brown, and P. Grafe Retigabine reduces the excitability of unmyelinated peripheral human axons Neuropharmacology 54 2008 1271 1278
23. M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N. Wierup, and M.A. Cenci Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur. J. Neurosci. 15 2002 120 132
24. S. Maljevic, T.V. Wuttke, and H. Lerche Nervous system KV7 disorders: breakdown of a subthreshold brake J. Physiol. 586 2008 1791 1801
25. G. Mueller-Schwefe Flupirtine in acute and chronic pain associated with muscle tenseness. Results of a postmarket surveillance study Fortschr. Med. Orig. 121 2003 11 18
26. K. Obermeier, G. Niebch, and K. Thiemer Pharmacokinetics and biotransformation of the analgesic flupirtine in the rat and dog Arzneimittel-Forschung 35 1985 60 67
27. J.A. Obeso, C.W. Olanow, and J.G. Nutt L-DOPA motor complications in Parkinson's disease Trends Neurosci. 23 Suppl. 10 2000 S2 S7
28. B. Ossola, N. Schendzielorz, S.H. Chen, G.S. Bird, R.K. Tuominen, P.T. Männistö, and J.S. Hong Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GNDF in astroglia Neuropharmacology 61 2011 574 582
29. C.Y. Ostock, K.B. Dupre, K.L. Eskow Jaunarajs, H. Walters, J. George, D. Krolewski, P.D. Walker, and C. Bishop Role of the primary motor cortex in l-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation Neuropharmacology 61 2011 753 760
30. M.A. Paquette, A.M. Anderson, J.R. Lewis, C.K. Meshul, S.W. Johnson, and S. Paul Berger MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism Neuropharmacology 58 2010 1002 1008
31. R.J. Porter, V. Nohria, and C. Rundfeldt Retigabine Neurotherapeutics 4 2007 149 154
32. A. Richter The genetically dystonic hamster: an animal model of paroxysmal dystonia M. LeDoux, Animal Models of Movement Disorders 2005 Elsevier Academic Press San Diego 459 466
33. A. Richter, and S.E. Sander Animal models of dyskinesias K. Kompoliti, Encyclopedia of Movement Disorders 2010 Elsevier Academic Press Oxford 85 89
34. sz mutant, an animal model of primary paroxysmal dystonia Br. J. Pharmacol. 149 2006 747 753
35. F. Richter, M. Hamann, and A. Richter Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice J. Neurosci. Res. 85 2007 681 691
36. I. Rivera-Arconada, and J.A. Lopez-Garcia Effects of M-current modulators on the excitability of immature rat spinal sensory and motor neurones Eur. J. Neurosci. 22 2005 3091 3098
37. C. Rundfeldt, and R. Netzer The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits Neurosci. Lett. 282 2000 73 76
38. M.J. Saganich, E. Machado, and B. Rudy Differential expression of genes encoding subthreshold-operating voltage-gated K+ channels in brain J. Neurosci. 21 2001 4609 4624
39. A. Schenzer, T. Friedrich, M. Pusch, P. Saftig, T.J. Jentsch, and J. Grotzinger Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine J. Neurosci. 25 2005 5051 5060
40. W.J. Schmidt, G. Schuster, E. Wacker, and G. Pergande Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs Eur. J. Pharmacol. 327 1997 1 9
41. G. Schuster, M. Schwarz, F. Block, G. Pergande, and W. Schmidt Flupirtine: a review of its neuroprotective and behavioral properties CNS Drug Rev. 4 1998 149 164
42. M. Schwarz, M. Nolden-Koch, J. Purr, G. Pergande, and F. Block Antiparkinsonian effect of flupirtine in monoamine-depleted rats J. Neural Transm. 103 1996 581 590
43. W. Shen, S.E. Hamilton, N.M. Nathanson, and D.J. Surmeier Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons J. Neurosci. 25 2005 7449 7458
44. C.C. Shieh, M. Coghlan, J.P. Sullivan, and M. Gopalakrishnan Potassium channels: molecular defects, diseases, and therapeutic opportunities Pharmacol. Rev. 52 2000 557 594
45. B. Spinnewyn, G. Mautino, J.G. Marin, M.N. Rocher, A.S. Grandoulier, E. Ferrandis, M. Auguet, and P.E. Chabrier BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease Neuropharmacology 60 2011 692 700
46. K. Steece-Collier, T.J. Collier, P.D. Danielson, R. Kurlan, D.M. Yurek, and J.R. Sladek Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats Mov. Disord. 18 2003 1442 1454
47. B.R. Thanvi, and T.C. Lo Long term motor complications of L-DOPA: clinical features, mechanisms, and management strategies Postgrad. Med. J. 80 2004 452 458
48. A. Thomas, D. Iacono, A.L. Luciano, K. Armellino, A. Di Iorio, and M. Onofrj Duration of amantadine benefit on dyskinesia of severe Parkinson's disease J. Neurol. Neurosurg. Psychiatr. 75 2004 141 143
49. S. Walsh, A.M. Gorman, D.P. Finn, and E. Dowd The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats Brain Res. 1363 2010 40 48
50. H.S. Wang, B.S. Brown, D. McKinnon, and I.S. Cohen Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991 Mol. Pharmacol. 57 2000 1218 1223
51. C. Winkler, D. Kirik, A. Björklund, and M.A. Cenci L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function Neurobiol. Dis. 10 2002 165 186
52. T.V. Wuttke, G. Seebohm, S. Bail, S. Maljevic, and H. Lerche The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate Mol. Pharmacol. 67 2005 1009 1017
53. P. Zhuang, Y. Li, and M. Hallett Neuronal activity in the basal ganglia and thalamus in patients with dystonia Clin. Neurophysiol. 115 2004 2542 2557